A brand name for ferumoxide (same as Endorem™)
Feridex® is a sterile aqueous colloid of superparamagnetic iron oxide associated with dextran for intravenous administration as a MRI contrast medium for the detection of liver lesions that are associated with an alteration in the RES.
Feridex® is taken up by macrophages, found only in healthy liver cells but not in most tumors. Tissues such as metastases, primary liver cancer, cysts and various benign tumors, adenomas and hyperplasia retain their native signal intensity, so the contrast between normal and abnormal tissue is increased. Feridex® is a black to reddish-brown aqueous colloid.
See also Ferumoxide.

In November 2008, AMAG Pharmaceuticals, Inc. decided to discontinue the manufacturing of Feridex.

A brand name for ferumoxide (same as Feridex®)
Endoremâ„¢ is a black to reddish-brown aqueous colloid of superparamagnetic iron oxide associated with dextran for intravenous administration as a MRI contrast medium for the detection of liver lesions that are associated with an alteration in the RES.
Endoremâ„¢ is taken up by macrophages, found only in healthy liver cells but not in most tumors. Tissues such as metastases, primary liver cancer, cysts and various benign tumors, adenomas and hyperplasia retain their native signal intensity, so the contrast between normal and abnormal tissue is increased.

See also Ferumoxide.

The company changed its name from Advanced Magnetics, Inc. to AMAG Pharmaceuticals, Inc. in July 2007.
AMAG Pharmaceuticals, Inc., a biopharmaceutical company, developed and manufactured organ-specific diagnostic contrast agents that provide clearer images during magnetic resonance imaging (MRI) tests used to detect tumors and other abnormalities.
The company had two MRI related products on the market: Feridex I.V. (for the diagnosis of liver lesions) and GastroMARK (used for bowel and abdominal MR imaging). In November 2008, AMAG Pharmaceuticals, Inc. decided to discontinue the manufacturing of Feridex. The development of Combidex as a contrast agent for lymph disease has also been stopped.
The Company has now two commercial products: Feraheme® and GastroMARK®. Feraheme® is the trade name of Ferumoxytol (formerly Code 7228) and is indicated for the treatment of iron deficiency anemia. Feraheme® is also being developed as a diagnostic agent for vascular-enhanced magnetic resonance imaging (MRI) to assess peripheral arterial disease.

MRI Contrast Agents:

South Korea-based company, which develops and distributes MRI (Feridex I.V.) and X-ray contrast media.

MRI Contrast Agents:

Argentina-based company, which distributes contrast media like Feridex I.V..

MRI Contrast Agents: